Treatment of Zollinger-Ellison Syndrome With Prevacid

Condition(s) targeted: Zollinger-Ellison Syndrome; Multiple Endocrine Neoplasia

Intervention: Lansoprazole (Prevacid) (Drug)

Phase: Phase 4

Status: Recruiting

Sponsored by: University of Alabama at Birmingham

Official(s) and/or principal investigator(s):
C. Mel I Wilcox, M.D., Principal Investigator, Affiliation: University of Alabama at Birmingham

Overall contact:
Toni Seay, M.S., Phone: 205-934-7332, Email: tamartin@uab.edu

The purpose of this study is to study the safety and efficacy of high dose Prevacid in the long-term treatment of patients who secrete abnormally large amounts of gastric acid.

Official title: Long-Term Study of the Efficacy and Safety of Lansoprazole in the Treatment of Zollinger-Ellison and Other Acid Hypersecretors

Study design: Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study

Primary outcome:

Long-term medical(non-surgical)control of gastric acid production

Medical control of symptoms

Secondary outcome: Prevention of relapse of symptoms, lesions & complications.

Detailed description: The aim of this protocol is to study the medical management of acid hypersecretory states including Zollinger-Ellison using Prevacid. The immediate objective is to heal peptic ulcers and eliminate symptoms and in the long term to prevent relapse of symptoms, lesions and complications. Other objectives include observation of the efficacy in controlling gastric acid production and of the safety of high dose, long-term use of Prevacid.

Minimum age: 19 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Diagnosed with Zollinger-Ellison syndrome

Exclusion Criteria:

- Pregnant or lactating females

Toni Seay, M.S., Phone: 205-934-7332, Email: tamartin@uab.edu

University of Alabama, Birmingham, Alabama 35294, United States; Recruiting

Starting date: March 2003
Ending date: April 2009
Last updated: July 7, 2008